Current Neuro-Oncology
Volume
26 Number 23
20 October 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 23, 20 October
Gkasdaris G, Berthiller J, Guyotat J, Jouanneau E, Gallet C,
Meyronet D, Thomas L, Cartalat S, Seyve A, Honnorat J, Ducray F,
Picart T.
Is Carmustine Wafer
Implantation in Progressive High-Grade Gliomas a Relevant
Therapeutic Option? Complication Rate, Predictors of Complications
and Onco-Functional Outcomes in a Series of 53 Cases.
Cancers
(Basel). 2024 Oct 12;16(20):3465. doi:
10.3390/cancers16203465. PMID:
39456559. Observational study. ˍ
Gonçalves JM, Ferreira F, Carvalho B, Polónia P,
Linhares P.
Survival Determinants in
Glioblastoma: An Insight into Biopsy-Only Patient
Outcomes.
Biomedicines.
2024 Oct 13;12(10):2327. doi:
10.3390/biomedicines12102327. PMID:
39457639. Observational study. ˍ
Chida D, Okita Y, Utsugi R, Kuroda H, Hirayama R, Kijima N,
Arisawa A, Kagawa N, Kanemura Y, Yoshimura S, Tomiyama N, Kishima
H.
Dynamic susceptibility
contrast‑enhanced perfusion magnetic resonance imaging
parameters for predicting MGMT
promoter methylation and prognostic value in newly diagnosed
patients with glioblastoma.
Oncol
Lett. 2024 Oct 14;28(6):610. doi:
10.3892/ol.2024.14741. PMID:
39493435. Observational study. ˍ
Gardner MM, Winter SF, Stahl F, Gerstner ER, Shih HA, Sherman J,
Dietrich J, Parsons MW.
Brain volume
loss after cranial irradiation: a controlled comparison study
between photon vs proton radiotherapy for WHO grade 2-3 gliomas.
J
Neurooncol. 2024 Oct 14. doi:
10.1007/s11060-024-04850-9. PMID:
39400662. Observational study˰
ˍ
He L, Chen M, Li H, Shi X, Qiu Z, Xu X.
Differentiation
between high-grade gliomas and solitary brain metastases based on
multidiffusion MRI model quantitative analysis.
Front
Oncol. 2024 Oct 14;14:1401748. doi:
10.3389/fonc.2024.1401748. PMID:
39469636. Observational study. ˍ
Campbell R, Shaw JM, Carlick T, Banks H, Faris MM, Jeon MS, Legge
DM, Foster C, Leonard R, Chan RJ, Agar MR, Miller A, Dhillon HM;
BRAINS Investigator Group.
"Such a
different type of tiredness": people with brain tumour, their
caregivers', and healthcare professionals' qualitative perceptions
of cancer-related fatigue.
J
Cancer Surviv. 2024 Oct 15. doi:
10.1007/s11764-024-01691-3. PMID:
39405030. Observational study. ˍ
Dwianingsih EK, Pranacipta S, Theresia E, Safitri S, Hartanto RA,
Malueka RG.
The role of the Ki-67
labelling index as an independent prognostic factor in indonesian
glioma patients.
Histol
Histopathol. 2024 Oct 15:18833. doi:
10.14670/HH-18-833. PMID:
39497648. Observational study. ˍ
Shimoda Y, Kanamori M, Yamashita S, Shibahara I, Umezawa R,
Mugikura S, Jingu K, Saito R, Sonoda Y, Kumabe T, Endo H.
Residual
pattern of the hyperintense area on T2-weighted magnetic resonance
imaging after initial treatment predicts the pattern and location
of recurrence in patients with newly diagnosed glioblastoma.
World Neurosurg. 2024 Oct 15:S1878-8750(24)01704-2.
doi: 10.1016/j.wneu.2024.10.012. PMID:
39419172. Observational study˰
ˍ
Res
Square
(Preprint).
2023 Aug 28. doi:
10.21203/rs.3.rs-3286164/v1.
ˍ
Duerinck J, Lescrauwaet L, Dirven I, Del'haye J, Stevens L,
Geeraerts X, Vaeyens F, Geens W, Brock S, Vanbinst AM, Everaert H,
Caljon B, Bruneau M, Lebrun L, Salmon I, Kockx M, Tuyaerts S,
Neyns B.
Intracranial administration
of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal
antibodies in patients with recurrent high-grade glioma.
Neuro
Oncol. 2024 Oct 16:noae177. doi:
10.1093/neuonc/noae177. PMID:
39406392. Interventional study. ˍ
Jin Y, Lu T, Liu B, Wang Y.
Epidemiology
and survival of primary intracranial malignant tumor patients with
drop metastasis: a population-based analysis.
Acta
Neurochir (Wien). 2024 Oct 16;166(1):413. doi:
10.1007/s00701-024-06309-2. PMID:
39412555. Observational study˰
ˍ
Kim S, Jung BK, Kim J, Jeon JH, Kim M, Jang SH, Kim CS, Jang H.
Anticancer effect of the oncolytic
Newcastle disease virus harboring the PTEN gene on glioblastoma.
Oncol
Lett. 2024 Oct 16;29(1):6. doi:
10.3892/ol.2024.14752. PMID:
39492938. Laboratory investigation. ˍ
Cai Z, Yang Z, Wang Y, Li Y, Zhao H, Zhao H, Yang X, Wang C, Meng
T, Tong X, Zheng H, He Z, Niu C, Yang J, Chen F, Yang Z, Zou Z, Li
W.
Tumor treating induced fields: a
new treatment option for patients with glioblastoma.
Front
Neurol. 2024 Oct 17;15:1413236. doi:
10.3389/fneur.2024.1413236. PMID:
39484048. Laboratory investigation. ˍ
Gately L, Drummond K, Dowling A, Bennett I, Freilich R, Phillips
C, Ahern E, Campbell D, Dumas M, Campbell R, Harrup R, Kim GY,
Reeves S, Collins IM, Gibbs P.
Evolving
Practice and Outcomes in Grade 2 Glioma: Real-World Data from a
Multi-Institutional Registry.
Cancers (Basel). 2024
Oct 17;16(20):3514. doi:
10.3390/cancers16203514. PMID:
39456608. Observational study. ˍ
Pak O, Kosianova A, Zaitsev S, Sharma A, Sharma H, Bryukhovetskiy
I.
Valproic Acid and Celecoxib Enhance
the Effect of Temozolomide on Glioblastoma Cells.
CNS
Neurol Disord Drug Targets. 2024 Oct 18. doi:
10.2174/0118715273330268241008220702. PMID:
39428930. Laboratory investigation˰
ˍ
Yuzkan S, Karagulle M, Sam Ozdemir M, Mutlu S, Kocak B.
Predictive Value of T2*-Weighted
Perfusion and T1-Weighted Permeability MRI Parameters in
Determining IDH Mutation Status and Grade of Gliomas.
Turk
Neurosurg. 2024 Oct 18. doi:
10.5137/1019-5149.JTN.46251-24.3. PMID:
39474970. Observational study. ˍ
*Su J, Guo S, Chen Z, Han Y, Yan J, Tang Q, Mao Y, Zhang H, Hou G,
Dong G, Guo C, Yang P.
Efficacy of
various extent of resection on survival rates of patients with
pilocytic astrocytoma: based on a large population.
Sci
Rep. 2024 Oct 20;14(1):24646. doi:
10.1038/s41598-024-75751-0. PMID:
39428432. Observational study. ˍ